OCUSERT PILO-20
LOE Approachingpilocarpine
NDAOPHTHALMICINSERT, EXTENDED RELEASEPriority Review
Approved
Jul 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
9
Data completeness
3/8 — Basic
Priority Review
OCUSERT PILO-20 (pilocarpine) is clinical pharmacology pharmacodynamics pilocarpine is a cholinergic parasympathomimetic agent exerting a broad spectrum of pharmacologic effects with predominant muscarinic action. First approved in 1974.
Drug data last refreshed 7h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OCUSERT PILO-20 is an extended-release ophthalmic insert containing pilocarpine, a cholinergic parasympathomimetic agent approved in 1974. It treats glaucoma and ocular hypertension by stimulating muscarinic receptors to increase aqueous humor outflow and reduce intraocular pressure. The drug causes miosis and accommodation spasm, with effects onset within hours and duration managed through the sustained-release formulation.
LOE Approaching
Product approaching loss of exclusivity with minimal linked job openings indicates a mature, likely declining commercial team focused on transition planning rather than growth.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics Pilocarpine is a cholinergic parasympathomimetic agent exerting a broad spectrum of pharmacologic effects with predominant muscarinic action. Pilocarpine, in appropriate dosage, can increase secretion by the exocrine glands. The sweat, salivary, lacrimal,…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.